{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:04Z","timestamp":1786982764041,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:00:00Z","timestamp":1501718400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Neurocrine Biosciences, Inc.","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s40268-017-0202-z","type":"journal-article","created":{"date-parts":[[2017,8,3]],"date-time":"2017-08-03T00:15:19Z","timestamp":1501719319000},"page":"449-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine"],"prefix":"10.1007","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6879-5052","authenticated-orcid":false,"given":"Heather","family":"Skor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan B.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gordon","family":"Loewen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F.","family":"O\u2019Brien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri E.","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haig","family":"Bozigian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,8,3]]},"reference":[{"issue":"18","key":"202_CR1","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1080\/14656566.2016.1258063","volume":"17","author":"J Jankovic","year":"2016","unstructured":"Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17(18):2461\u201370.","journal-title":"Expert Opin Pharmacother."},{"issue":"6","key":"202_CR2","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1002\/hlca.19580410634","volume":"41","author":"A Brossi","year":"1958","unstructured":"Brossi A, Chopard-dit-Jean LH, Schnider O. Syntheseversuche in der emetin-reihe. 3. Mitteilung. 2-hydroxy-hydrobenzo[a]chinolizine. Helv Chim Acta. 1958;41(6):1793\u2013806.","journal-title":"Helv Chim Acta."},{"issue":"1\u20132","key":"202_CR3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.autneu.2006.04.004","volume":"128","author":"R Mart\u00ednez-Olivares","year":"2006","unstructured":"Mart\u00ednez-Olivares R, Villanueva I, Racotta R, Pi\u00f1\u00f3n M. Depletion and recovery of catecholamines in several organs of rats treated with reserpine. Auton Neurosci. 2006;128(1\u20132):64\u20139.","journal-title":"Auton Neurosci."},{"key":"202_CR4","unstructured":"Xenaxine [package insert]. Deerfield, IL: Lundbeck; 2015."},{"issue":"1","key":"202_CR5","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/S0026-895X(25)15021-9","volume":"25","author":"D Scherman","year":"1984","unstructured":"Scherman D, Henry JP. Reserpine binding to bovine chromaffin granule membranes. Characterization and comparison with dihydrotetrabenazine binding. Mol Pharmacol. 1984;25(1):113\u201322.","journal-title":"Mol Pharmacol."},{"issue":"3","key":"202_CR6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/0014-2999(95)00162-E","volume":"278","author":"M Kilbourn","year":"1995","unstructured":"Kilbourn M, Lee L, Vander Borght T, Jewett D, Frey K. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol. 1995;278(3):249\u201352.","journal-title":"Eur J Pharmacol."},{"key":"202_CR7","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1124\/jpet.116.239160","volume":"361","author":"DE Grigoriadis","year":"2017","unstructured":"Grigoriadis DE, Smith E, Hoare SR, Madan A, Bozigian H. Pharmacologic characterization of valbenazine (NBI-98854) and its metabolites. J Pharmacol Exp Ther. 2017;361:454\u201361.","journal-title":"J Pharmacol Exp Ther."},{"issue":"11","key":"202_CR8","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","volume":"11","author":"J Jankovic","year":"2011","unstructured":"Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509\u201323.","journal-title":"Expert Rev Neurother."},{"issue":"5","key":"202_CR9","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.ejmech.2011.02.046","volume":"46","author":"Z Yao","year":"2011","unstructured":"Yao Z, Wei X, Wu X, Katz JL, Kopajtic T, Greig NH, et al. Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors. Eur J Med Chem. 2011;46(5):1841\u20138.","journal-title":"Eur J Med Chem."},{"issue":"1","key":"202_CR10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/(SICI)1520-636X(1997)9:1<59::AID-CHIR11>3.0.CO;2-P","volume":"9","author":"MR Kilbourn","year":"1997","unstructured":"Kilbourn MR, Lee LC, Heeg MJ, Jewett DM. Absolute configuration of (+)-alpha-dihydrotetrabenazine, an active metabolite of tetrabenazine. Chirality. 1997;9(1):59\u201362.","journal-title":"Chirality."},{"key":"202_CR11","volume-title":"Huntington\u2019s Disease: New Insights for the Healthcare Professional","author":"QA Acton","year":"2011","unstructured":"Acton QA. Huntington\u2019s Disease: New Insights for the Healthcare Professional. Atlanta, Georgia: ScholarlyEditions; 2011."},{"key":"202_CR12","unstructured":"Nitoman (tetrabenazine) 25\u00a0mg tablets. Irish Medicines Board, summary of product characteristics; April 2014."},{"issue":"3","key":"202_CR13","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/WNF.0b013e318290cd41","volume":"36","author":"PA LeWitt","year":"2013","unstructured":"LeWitt PA. Tardive dyskinesia caused by tetrabenazine. Clin Neuropharmacol. 2013;36(3):92\u20133.","journal-title":"Clin Neuropharmacol."},{"issue":"10","key":"202_CR14","first-page":"797","volume":"68","author":"FJ Marshall","year":"2007","unstructured":"Marshall FJ, Fahn S, Clarence-Smith K. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial [author reply to correspondence]. Neurology. 2007;68(10):797.","journal-title":"Neurology."},{"issue":"Suppl S1","key":"202_CR15","first-page":"S213","volume":"41","author":"D Grigoriadis","year":"2016","unstructured":"Grigoriadis D, Comella C, Remington G, Jimenez R, Burke J, O\u2019Brien C. Efficacy of valbenazine (NBI-98854) in subjects with tardive dyskinesia: results of a long-term extension study (KINECT 3 extension) [abstract]. Neuropsychopharmacol. 2016;41(Suppl S1):S213.","journal-title":"Neuropsychopharmacol"},{"key":"202_CR16","unstructured":"U.S. Food and Drug Administration. Xenazine (tetrabenazine) tablets (drug approval package) 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2008\/021894s000TOC.cfm ."},{"issue":"6","key":"202_CR17","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/jps.2600760610","volume":"76","author":"R Mehvar","year":"1987","unstructured":"Mehvar R, Jamali F. Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm Sci. 1987;76(6):461\u20135.","journal-title":"J Pharm Sci."},{"issue":"12","key":"202_CR18","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/00004647-199912000-00011","volume":"19","author":"RA Koeppe","year":"1999","unstructured":"Koeppe RA, Frey KA, Kuhl DE, Kilbourn MR. Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11c]dihydrotetrabenazine. J Cereb Blood Flow Metab. 1999;19(12):1376\u201384.","journal-title":"J Cereb Blood Flow Metab."},{"key":"202_CR19","unstructured":"U.S. Food and Drug Administration. Tetrabenazine briefing document for peripheral and central nervous system advisory committee. 2007. https:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/briefing\/2007-4328b1-02-Prestwick.pdf ."},{"key":"202_CR20","unstructured":"Austedo [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2017."}],"container-title":["Drugs in R&amp;D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-017-0202-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0202-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-017-0202-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T16:13:42Z","timestamp":1750781622000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-017-0202-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["202"],"URL":"https:\/\/doi.org\/10.1007\/s40268-017-0202-z","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}